Antiplatelet Therapy in Peripheral Artery Disease
Peripheral artery disease (PAD) is a term that relates to atherosclerosis and narrowing of the arteries in the lower extremities. The prevalence of PAD is approximately 12% of the adult population. Despite the low rate of peripheral complications and ampu
- PDF / 454,576 Bytes
- 17 Pages / 439.37 x 666.142 pts Page_size
- 91 Downloads / 233 Views
Contents 1 Epidemiology and Classification of PAD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 Management of PAD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Antiplatelet Drugs in PAD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Aspirin and PAD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Nonaspirin Drugs and PAD Inhibiting the Platelet Arachidonic Acid Pathway . . . . . . . . . 6 Nonaspirin Drugs Inhibiting Platelet ADP Receptors and PAD . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Comparison of Efficacy of Antiplatelet Treatments in PAD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
548 552 553 553 557 558 559 560 561
Abstract Peripheral artery disease (PAD) is a term that relates to atherosclerosis and narrowing of the arteries in the lower extremities. The prevalence of PAD is approximately 12% of the adult population. Despite the low rate of peripheral complications and amputation, PAD is complicated by a high rate of cardiovascular events including myocardial infarction, stroke, and vascular death with an annual incidence of about 5%. The detection of PAD is initially based on the appearance of typical symptoms (claudication and critical limb ischemia) related to peripheral arterial insufficiency. However, PAD may also be present in the absence of clinical symptoms (asymptomatic PAD). Accordingly, asymptomatic disease may occur in up to 50% of all patients with PAD. Ankle brachial index (ABI) is a diagnostic test used to evaluate
F. Violi (*) • S. Basili Prima Clinica Medica, Sapienza-University of Rome, Rome, Italy e-mail: [email protected] J.S. Berger NYU Langone Medical Center, New York, NY, USA W.R. Hiatt (*) University of Colorado School of Medicine and CPC Clinical Research, Aurora, CO, USA e-mail: [email protected] P. Gresele et al. (eds.), Antiplatelet Agents, Handbook of Experimental Pharmacology 210, DOI 10.1007/978-3-642-29423-5_22, # Springer-Verlag Berlin Heidelberg 2012
547
548
F. Violi et al.
the presence of PAD, defined by an ABI 0.90. The ABI is also demonstrated to be useful in the assessment of vascular risk in asymptomatic and symptomatic patients. Antiplatelet therapy remains a key intervention to reduce cardiovascular risk in PAD. Data from Antithrombotic Trialists’ Collaboration showed that antiplatelet treatment was associated with a 23% risk
Data Loading...
